early at 3 months in both groups, afterwards IFNG and IL10 levels were sustained
while TGFB1 showed a slightly increase after 1 year in responders.
Conclusion Our findings are in agreement with an immune re-activation after imatinib
initiation, especially on patients who achieved an optimal molecular response; however, some
immune mediators may require a longer exposition. The follow-up of novel and reliable
biomarkers, such as ARG1, one of the principal mechanisms of myeloid-derived-suppressor
cells to inhibit immune system, may be useful to deepen the characterization of early
responder patients.
